CTOR NASDAQ
Citius Oncology, Inc.
1W: -9.5%
1M: +22.2%
3M: +34.0%
YTD: -12.0%
1Y: -51.8%
$0.95
-0.03 (-3.06%)
Weekly Expected Move ±13.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$88.3M
52W Range0.491-2.25
Volume208,398
Avg Volume86,612
Beta3.53
Dividend—
Analyst Ratings
Company Info
CEOLeonard L. Mazur
Employees285
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2022-12-08
11 Commerce Drive
Cranford, NY 07016
US
Cranford, NY 07016
US
347-627-0058
About Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Latest News
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6% – Here’s What Happened
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Peri Jonathan | 0 | — | 2026-08-10 | |
| HOLUBIAK MYRON Z | A-Award | 850,000 | — | 2025-09-19 |
| HOLUBIAK MYRON Z | A-Award | 100,000 | — | 2025-09-19 |
| Smith Robert Joseph | A-Award | 300,000 | — | 2025-09-19 |
| Mazur Leonard L | A-Award | 1,700,000 | — | 2025-09-19 |